The Preconceptional Level of Peripheral Natural Killer Cells which was Expected to Bring Successful Treatment Outcome using Low-dose Intravenous Gamma Immunoglobulin (IVIg) Infusion in Patients with Recurrent Spontaneous Abortion.
- Author:
Sun Hwa CHA
1
;
Hae Suk KIM
;
Hye Ok KIM
;
In Ok SONG
;
Keun Jai YOO
;
Mi Kyung KOONG
;
Inn Soo KANG
;
Kwang Moon YANG
Author Information
1. Department of Obstetrics and Gynecology, Samsung Cheil Hospital & Women's Healthcare Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ykm2955@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Recurrent spontaneous abortion;
Natural killer cell;
Intravenous immunoglobulin
- MeSH:
Abortion, Habitual;
Abortion, Spontaneous*;
Discrimination (Psychology);
Female;
Gestational Sac;
Humans;
Immunoglobulins*;
Immunoglobulins, Intravenous;
Killer Cells, Natural*;
Live Birth;
Pregnancy;
Pregnancy Outcome;
ROC Curve;
Treatment Outcome*
- From:Korean Journal of Fertility and Sterility
2005;32(3):217-222
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: We aimed to investigate the clinical effect of low-dose intravenous immunoglobulin treatment in unexplained recurrent spontaneous aborters (RSA) with elevated peripheral CD56+ natural killer (NK) cell levels and to determine the pre-conceptional NK cell percentage predictive of subsequent successful pregnancy outcome. MATERIALS AND METHODS: Sixty four cases of unexplained recurrent miscarriage with elevated peripheral NK cells (>15%) were received low dose IVIg infusion at the dosage of 400 mg/Kg/month after confirmation of gestational sac and continued until 20 weeks. The patients were divided into two groups according to the pregnancy outcome: Group I was success of treatment defined as live birth at or after 25 gestational weeks and Group II was failure of treatment. The preconceptional levels of the peripheral blood NK cells were compared between two groups. RESULTS: Fifty-three pregnancies resulted in live births after 25 weeks and 11 resulted in abortion (Overall success rate of IVIG treatment was 82.8%). Preconceptional CD56+ NK cell percentage in group II (27.4+/-1.9%) was higher than those in group I (22.3+/-0.8%). By using ROC curve, optimal discrimination between success and failure of treatment was achieved with < or = 27% of preconceptional NK cell percentage. CONCLUSION: In RSA patients with elevated NK cells, we suggest that preconceptional peripheral blood CD56+ NK cell level could be a useful marker for predicting successful treatment outcome of low-dose IVIg infusion.
